Single-Chamber and Dual-Chamber Pacemakers: How They Work, What the Evidence Shows

2. What It Is

A pacemaker is an implanted electronic device that delivers electrical stimuli to the heart muscle to initiate or regulate the cardiac rhythm when the heart’s own electrical system fails to do so adequately.

A pacemaker system consists of:

The pulse generator (the “pacemaker”): A titanium case housing a lithium iodide battery (lasting approximately 8-15 years depending on pacing demand and programming), a microprocessor, sensing circuitry, pacing output circuitry, memory for episode storage, and wireless telemetry for programming and interrogation. The pulse generator is typically implanted subcutaneously in the left or right upper chest (the “pocket”), below the clavicle.

The lead(s): Insulated wires that connect the pulse generator to the heart. Each lead passes through the subclavian or cephalic vein, through the superior vena cava, into the right heart. A single-chamber pacemaker uses one lead in the right ventricle (RV) or right atrium (RA). A dual-chamber pacemaker uses two leads: one in the right atrium and one in the right ventricle. Each lead’s tip anchors to the endocardium (the inner heart surface) via either a passive tine fixation or an active helix-screw mechanism.

Configuration terminology:

• VVI: Single-chamber RV pacing. Paces and senses in the ventricle. Inhibited by a native ventricular signal (V=ventricle, V=ventricle, I=inhibited). The simplest pacemaker. Used for AF with slow ventricular rate (where atrial synchrony is already lost).
• AAI: Single-chamber atrial pacing. Paces and senses in the atrium. Used for sinus node dysfunction with intact AV conduction.
• DDD: Dual-chamber pacing. Paces and senses in both chambers. Tracks atrial rate and triggers ventricular pacing after a programmed AV interval if the native AV conduction is too slow or absent. The dominant mode for patients with sinus node dysfunction plus or minus AV block.
• DDDR: Rate-responsive dual-chamber pacing. The added “R” indicates a rate-adaptive function using a motion sensor (accelerometer) or minute ventilation sensor to increase pacing rate during exercise, mimicking the normal chronotropic response.

Major manufacturers: Medtronic (Micra, Ensura, Azure, Compia families), Abbott (Assurity, Endurity, Assurity Plus families), Boston Scientific (Accolade, Altrua 2 families), Biotronik (Evity, Edora, Effecta families). All currently available pacemakers are FDA-approved under PMA pathways. All major current-generation devices from these manufacturers offer MRI-conditional labeling under specified conditions.

3. The Mechanism

3.1 The Normal Cardiac Electrical System

Understanding a pacemaker requires understanding what it replaces.

The sinoatrial (SA) node, located at the junction of the superior vena cava and the right atrium, is the heart’s intrinsic pacemaker. Its spontaneous depolarization rate is approximately 60-100 bpm in a resting adult, modulated upward by sympathetic (adrenaline) activation and downward by parasympathetic (vagal) inhibition. The SA node fires; the electrical impulse spreads across both atria, producing atrial contraction (the P wave on ECG).

The impulse reaches the atrioventricular (AV) node at the junction of the atria and ventricles. The AV node deliberately slows conduction, creating the PR interval delay (0.12-0.20 seconds in normal adults). This delay allows the atria to contract and empty blood into the ventricles before ventricular contraction begins. AV delay is not a defect; it is a feature.

From the AV node, the impulse travels down the His bundle (a specialized conduction pathway), then into the left and right bundle branches, then into the Purkinje fiber network throughout the ventricular myocardium. This rapid, synchronized spread of electrical activation produces the QRS complex and coordinates the left and right ventricles to contract simultaneously.

3.2 Demand Pacing: The Core Principle

A pacemaker in demand mode (VVI or DDD) behaves like a sentinel: it watches for the heart’s own electrical activity and paces only if the heart fails to generate an impulse within a programmed escape interval.

Sensing: The lead tip senses local electrical activity (a P-wave at the atrial lead tip; a QRS at the ventricular lead tip). When a signal exceeding the sensing threshold is detected, the pacemaker’s timing interval is reset. It waits again for a native signal.

Pacing: If no native signal is sensed within the escape interval, the pacemaker delivers a pacing stimulus: a brief electrical pulse (typically 0.4-1.0 ms duration, 1.0-3.5 V amplitude) that depolarizes the adjacent myocardium and initiates a heartbeat.

Inhibition: If a native signal is sensed before the escape interval expires, the pacemaker is inhibited. It does not pace. This prevents pacing on top of native rhythm (which could, in extreme cases, deliver a stimulus during the vulnerable period of repolarization).

Rate-adaptive pacing (DDDR/VVIR): An accelerometer within the pulse generator detects body motion. When motion increases (consistent with exercise), the pacing rate increases from the base rate toward a programmed sensor-driven upper rate. This simulates the normal heart’s acceleration during activity.

3.3 AV Synchrony: Why Dual-Chamber Beats Single-Chamber in Most Patients

In sinus rhythm, the atria contract first and add approximately 15-30% to ventricular filling (the “atrial kick”). This presystolic filling is especially important in patients with reduced ventricular compliance (hypertension-related diastolic dysfunction, hypertrophic cardiomyopathy, restrictive physiology).

A single-chamber RV pacemaker (VVI) paces the ventricle without regard to atrial activity. The atria contract independently, sometimes against a closed tricuspid valve, producing the “cannon A wave” phenomenon and AV dyssynchrony. The loss of AV synchrony reduces cardiac output by up to 20% in patients with diastolic dysfunction.

A dual-chamber pacemaker (DDD) tracks atrial activity: when the SA node fires and produces a P-wave, the atrial lead senses it, initiates the AV delay timer, and triggers ventricular pacing at the end of the AV delay if native AV conduction does not arrive in time. The result: atrial contraction followed by ventricular contraction at the appropriate AV interval. AV synchrony is preserved.

Pacemaker syndrome: When a VVI pacemaker is implanted in a patient who has intact ventriculoatrial (VA) retrograde conduction, ventricular pacing can activate the atria retrogradely, causing the atria to contract against closed AV valves. The resulting pressure wave is sensed by the atrial baroreceptors, producing symptoms: pulsations in the neck, lightheadedness, fatigue, and reduced exercise capacity. Pacemaker syndrome is a complication of VVI pacing that is largely avoided by dual-chamber programming.

3.4 Right Ventricular Pacing and Dyssynchrony

A critically important limitation of right ventricular apical pacing: pacing from the RV apex produces a left bundle branch block (LBBB)-like activation pattern, spreading from the right ventricle to the left ventricle across the interventricular septum rather than down the His-Purkinje system. This LBBB-pattern activation is mechanically dyssynchronous: the right ventricle contracts before the left, and the lateral left ventricular wall is the last to activate.

In patients with normal LV function, this dyssynchrony may have minimal short-term consequences. Over years, in some patients, high-burden RV pacing (>40% of beats paced from RV) is associated with LV dilatation, LV dysfunction, and development of pacing-induced cardiomyopathy.

This observation has driven interest in alternative pacing strategies that preserve physiological conduction:

His-bundle pacing (HBP): Pacing directly on the His bundle, engaging the normal conduction system and producing narrow QRS complexes without ventricular dyssynchrony.

Left bundle branch pacing (LBBP): Pacing the left bundle branch directly or via the interventricular septum, producing a narrow or nearly-narrow QRS complex.

Conduction system pacing (CSP): The umbrella term for His-bundle and left bundle branch pacing as alternatives to conventional RV apical pacing.

CSP is technically more demanding than standard RV pacing but is increasingly performed at centers with EP expertise. The evidence base for CSP as a clinical improvement over conventional RV pacing is growing 4 / Promising but the randomized outcome trials comparing CSP vs conventional pacing are ongoing or not yet mature.

4. How It Is Used

4.1 Indications for Pacemaker Implantation

The 2018 ACC/AHA/HRS Guideline on Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay provides the current indication framework.

Class I (indicated):

• Symptomatic sinus bradycardia (documented correlation between symptoms and bradycardia)
• Sinus node dysfunction with symptomatic chronotropic incompetence
• Third-degree (complete) AV block, regardless of symptoms (high risk of progression and sudden death)
• Symptomatic second-degree Mobitz II AV block (infranodal block with risk of complete heart block)
• Bifascicular block with syncope and documented complete heart block on EP study
• Symptomatic sinus pauses > 3 seconds during waking hours

Class II (reasonable or may be considered):

• Asymptomatic sinus pause > 3 seconds during sleep
• First-degree AV block with symptoms attributable to loss of AV synchrony (pacemaker syndrome without a pacemaker)
• Congenital complete heart block in adults

Class III (not indicated):

• Asymptomatic bradycardia with rate > 40 bpm and no significant pauses
• Reversible bradycardia (medication-induced, hypothyroid, hypervagal)
• Asymptomatic first-degree AV block
• Asymptomatic Mobitz I (Wenckebach) AV block at the level of the AV node

4.2 The Programming Decision: Mode and Rate

Programming a pacemaker is not set-and-forget. The device is programmed at implantation and reprogrammed at follow-up as clinical needs change.

Key programming parameters:

• Lower rate limit: The minimum rate below which the pacemaker will pace (typically 60 bpm at rest; 50 bpm for athletes)
• AV delay: The time allowed for native AV conduction before the device triggers ventricular pacing (typically 150-220 ms; shorter for higher heart rates to mimic physiological rate adaptation)
• Upper rate limit: The maximum tracking rate in DDD mode (prevents the pacemaker from tracking very fast atrial rates, e.g., during AF with rapid conduction)
• Rate-adaptive settings: Sensor sensitivity (how much motion triggers rate increase) and rate-response slope

For patients with intact native SA node function who need pacing only for AV block: the AV delay is programmed to allow native conduction whenever possible (long AV delay), minimizing RV pacing burden. The goal is to pace as little as necessary.

For patients with complete AV block and RV pacing: the AV delay is programmed shorter to deliver consistent dual-chamber pacing. Conduction system pacing (HBP or LBBP) is increasingly considered to minimize the long-term LV dyssynchrony risk in these patients.

4.3 Geographic Access

Pacemaker implantation is available at most regional medical centers in Illinois. For standard pacemaker implantation (VVI or DDD), the procedure does not require an electrophysiology specialist in most cases; a general or interventional cardiologist with pacing experience can perform the implantation.

For complex cases (conduction system pacing, lead extraction, pacemaker-dependent patients with complex anatomy): Carle Foundation Hospital in Urbana, University of Illinois Hospital in Chicago, and Northwestern Medicine have the electrophysiology expertise to manage these cases.

For patients in far southern Illinois or far western Illinois: OSF HealthCare (Peoria, Bloomington, Galesburg), SIU Medicine (Springfield), and Memorial Hospital (Belleville) provide pacemaker services. Very remote rural patients may need temporary pacing in a local hospital and transfer for permanent device implantation.

5. The Evidence

5.1 Pacemaker vs No Pacemaker in Symptomatic Sick Sinus Syndrome

Multiple retrospective and registry studies have established that symptomatic sick sinus syndrome untreated is associated with significant morbidity (recurrent syncope, falls, injury, AF development) and mortality risk. No randomized placebo-controlled trial of pacemaker vs no pacemaker for symptomatic sick sinus syndrome exists (ethical constraints preclude randomizing patients with documented symptomatic bradycardia to no treatment); the clinical benefit is considered established by accumulated evidence.

5.2 Dual-Chamber vs Single-Chamber Pacing: UKPACE and MOST Trials

MOST Trial (2002, NEJM): 2,010 patients with sick sinus syndrome randomized to DDDR vs VVIR pacing. Primary outcome: time to death or nonfatal stroke.

Results: No significant difference in mortality or stroke between modes. However, DDDR pacing significantly reduced AF incidence (20.8 per 100 person-years vs 27.1 with VVIR; RR 0.79), reduced pacemaker syndrome (12.2% in VVIR group crossed over due to pacemaker syndrome), and improved quality of life.

Conclusion: For sick sinus syndrome, dual-chamber pacing does not reduce mortality vs single-chamber pacing but reduces pacemaker syndrome and AF burden. Current practice favors dual-chamber for sick sinus syndrome.

UKPACE Trial (2005, NEJM): 2,021 patients age 70+ with high-degree AV block randomized to VVIR vs either VDD or DDD. No significant mortality difference at 3 years.

Conclusion: For AV block in older patients, VVI single-chamber pacing is not inferior to dual-chamber for mortality. However, AV synchrony benefits (quality of life, pacemaker syndrome reduction) still favor dual-chamber in most patients with intact sinus function.

Practical current guidance: In patients with sick sinus syndrome (intact AV node), dual-chamber pacing is preferred. In patients with chronic AF and AV block (no P-wave to track), single-chamber VVI is appropriate. In patients with AV block and intact sinus node function, dual-chamber is preferred to preserve AV synchrony.

5.3 Minimizing RV Pacing: The MVP Algorithm

In the landmark Managed Ventricular Pacing (MVP) trial, Gillis et al. demonstrated that programming pacemakers to minimize unnecessary RV pacing using algorithms that promote native AV conduction (such as Medtronic’s MVP mode) reduced the incidence of AF and heart failure hospitalizations compared to conventional DDD programming with fixed short AV delays.

This finding has materially changed pacemaker programming practices: the default is now to program the longest AV delay clinically acceptable to allow native conduction whenever possible, reserving RV pacing for moments when native conduction fails.

5.4 HIS-SYNC and Conduction System Pacing Evidence

A growing body of evidence supports His-bundle pacing as producing more physiological ventricular activation than RV apex pacing:

His-SYNC Pilot Study (Lustgarten 2015): Crossover between HBP and conventional RV pacing in cardiac resynchronization candidates. HBP produced narrower QRS, superior hemodynamics, and equivalent safety.

HOPE-HF Trial (2021): His-bundle pacing in patients with HFrEF and prolonged PR interval. Primary outcome: 6-minute walk distance. Result: modest non-significant improvement. A subset with PR >200 ms showed significant benefit.

4 / Promising 00131-8)

CSP evidence is evolving rapidly. A definitive large RCT of CSP vs conventional RV pacing for routine pacemaker patients is needed and multiple trials are ongoing.

5.5 Pacemaker Complications: WRAP-IT Trial

Pacemaker pocket infections are uncommon but serious. The WRAP-IT trial randomized 6,983 patients undergoing pacemaker implantation or revision to antibiotic envelope (Tyrx absorbable antibacterial envelope, which elutes rifampin and minocycline at the pocket site) vs standard care.

Results: Major CIED infection at 12 months: 0.7% in envelope group vs 1.2% in control (HR 0.60, 95% CI 0.36-1.00). The reduction met the pre-specified superiority threshold.

The antibiotic envelope is indicated for patients at raised infection risk: prior CIED infection, diabetes, renal failure, immunosuppression, device revision.

5.6 MRI-Conditional Pacemakers

Legacy pacemakers were considered MRI-unsafe due to lead heating, lead movement, and pacemaker inhibition by radiofrequency fields. The development of MRI-conditional devices (Medtronic Ensura/Percepta families, Abbott Endurity/Assurity families, Boston Scientific Accolade family, all with FDA PMA with MRI-conditional labeling) has substantially changed this.

Current MRI-conditional pacemakers can be scanned at 1.5T and many at 3.0T with:

• Specific programming mode activated before scanning (e.g., asynchronous pacing to prevent RF field inhibition)
• Avoidance of certain scan coil configurations at the device
• Monitoring during scanning

For pacemaker-dependent patients (no escape rhythm if pacing fails), scanning with the device in asynchronous mode provides a pacing backup while scanning proceeds. This is safe in current-generation conditional devices.

For patients with older (non-conditional) devices: MRI is performed only when no alternative imaging exists and when the clinical benefit clearly exceeds the risk, under direct EP oversight.

6. The Patient Experience

6.1 The Implantation

The patient receives local anesthesia (lidocaine infiltration) at the pocket site. Light IV sedation (midazolam, fentanyl) is administered for comfort. The skin is incised, a pocket is created in the subcutaneous tissue (most commonly just below the left clavicle), and the lead(s) are introduced through the axillary or cephalic vein and advanced fluoroscopically into the heart.

Lead positioning is confirmed by fluoroscopy and by testing pacing and sensing thresholds at the intended fixation site. Once target thresholds are obtained, the lead helix is deployed (active fixation leads) or the tines engage the trabecular (passive fixation leads). The lead is secured to the pectoral fascia and connected to the pulse generator. The pocket is closed in layers.

Total procedure time: 45-90 minutes for a standard dual-chamber implant.

The next 24 hours: Patients typically stay overnight in a monitored bed. An anterior-posterior chest X-ray confirms lead position and excludes pneumothorax (a risk of subclavian venous access; reduced with axillary vein approach). Device programming is completed at the bedside. Patients are discharged home the following morning with activity restrictions.

6.2 Activity Restrictions Post-Implant

The first 4-6 weeks after pacemaker implantation:

• No lifting the ipsilateral arm above the shoulder (to prevent lead dislodgement during the period before fibrous tissue anchors the lead)
• No driving for 48 hours to 1 week (jurisdiction- and institution-specific)
• Wound care: keep incision dry for 48-72 hours, no soaking

After 6 weeks:

• Return to full activity, including exercise
• Seatbelt use with chest pad to reduce discomfort from belt pressure on the pocket in the first months

The most common patient concern: “Can I use my phone?” Yes. Modern smartphones do not interfere with pacemaker function at typical use distances (greater than 6 inches from the device). The concern was primarily relevant to older analog phones and early digital models. Current generation pacemakers are shielded against typical consumer device electromagnetic fields.

6.3 Device Follow-Up

Pacemakers require regular follow-up:

• Initial post-implant check: 6-8 weeks
• Routine follow-up: every 6-12 months via in-person or remote clinic visit
• Remote monitoring: most current-generation pacemakers transmit data daily or nightly via home communicators, enabling between-visit review

At follow-up, the cardiologist or device clinic nurse:

• Interrogates the device (reviews battery status, lead parameters, stored episodes, pacing percentages)
• Reviews any transmitted alerts or arrhythmia episodes
• Adjusts programming as clinical needs change
• Projects battery longevity (based on pacing demand and current battery voltage)

When the battery approaches end-of-life (typically 3-6 months before depletion), the generator is replaced in a generator change procedure. The existing leads are typically preserved if they are functioning adequately; new leads are placed only if prior leads have failed. Generator replacement is less invasive than the original implant: the pocket is reopened, the old generator disconnected, the new generator connected, and the pocket closed.

7. Decisions and Trade-Offs

7.1 The AV Block Patient: How Urgently Does a Pacemaker Need to Be Placed?

This depends on the degree of block and the clinical context:

Complete (third-degree) AV block: Requires pacing. The urgency depends on the patient’s hemodynamic status and escape rate. Complete heart block with escape rate below 40 bpm or hemodynamic compromise: urgent; temporary pacing bridge until permanent pacemaker implantation. Complete heart block with stable escape rate of 50-60 bpm and hemodynamically stable: semi-urgent (within 48-72 hours). Complete heart block caused by inferior MI: may be transient; temporary pacing first, reassess at 72 hours before permanent device.

Symptomatic Mobitz II block: Class I indication. Semi-urgent (same admission or within days). Risk of progression to complete heart block.

Symptomatic sick sinus syndrome with documented pauses: Elective, semi-urgent to urgent depending on pause duration and symptoms. Ruth’s 4.7-second pause during waking hours was urgent enough to schedule the procedure within one week.

7.2 Pacemaker Dependency

Some patients with intermittent AV block or sick sinus syndrome may have adequate native rhythm for hours or days. Other patients are completely pacemaker-dependent (no escape rhythm whatsoever if the pacemaker fails; immediate asystole). Knowing the patient’s level of dependence informs:

• Antibiotic envelope decision (dependent patients more adversely affected by infection requiring device removal)
• MRI planning (dependent patients require extra precaution with asynchronous programming during scans)
• Travel planning (dependent patients should know the nearest hospital at all times)

7.3 Single-Chamber vs Dual-Chamber: Practical Decision Framework

7.4 Leadless Pacemaker Consideration

For patients where traditional transvenous lead placement is technically challenging (absent venous access, prior cardiac surgery with adherent pericardium, infection risk requiring no transvenous hardware), the Micra leadless pacemaker (see DEVI-011) provides single-chamber pacing without transvenous leads. The trade-off: Micra provides only single-chamber pacing (no dual-chamber synchrony, though Micra AV offers a limited synchrony approximation via mechanical sensing).

8. The SDE Synthesis

Ruth’s pacemaker changed her life in a specific, measurable way: she stopped falling. She stopped being afraid of walking to her mailbox alone. She resumed her morning walk in the neighborhood she had been avoiding for months out of fear of another syncopal episode.

That quality-of-life restoration is worth naming explicitly. Pacemakers in cardiology occupy an unusual position: they are not medicines that reduce future risk. They are devices that fix a current, daily, immediate problem. Ruth’s bradycardia was not a future risk factor. It was a present reality that was injuring her, isolating her, and threatening her independence.

The Stop Dying Early framework focuses primarily on prevention: identifying cardiovascular risk factors before they produce events, treating them before the first MI, the first stroke, the first sudden death. Pacemakers operate in a different clinical space: they treat a present electrical failure of the heart’s wiring system. They do not prevent atherosclerosis. They do not reduce ApoB. They do not increase VO2max.

But they prevent the deaths and injuries that occur in the interim between the development of bradycardia and the clinical recognition that it is dangerous. Ruth’s three syncopal episodes before her pacemaker implantation had produced one significant fall with bruising, one episode of cognitive confusion lasting several hours (likely from cerebral hypoperfusion during the 4.7-second pause), and a progressive deterioration in confidence and independence that was making her home unsafe to live in alone.

The pacemaker restored her to herself. That is neither trivial nor purely technical. It is the outcome that matters.

For patients in the SDE program who are being evaluated for bradycardia, syncope, or chronotropic incompetence, the pacemaker decision algorithm follows the 2018 ACC/AHA/HRS guidelines. The SDE Audit for a patient with documented bradycardia includes a full assessment of symptoms, ambulatory ECG data, electrolytes and thyroid function, medication review (many common medications cause iatrogenic bradycardia: beta-blockers, diltiazem, verapamil, digoxin, amiodarone), and echocardiographic assessment for structural disease. The pacemaker indication, when present, is documented clearly with its evidence class, and the patient is referred for implantation at a facility with appropriate expertise.

SDE Offer Routing:

• SDE Audit (Tier 1): Full bradycardia evaluation with ambulatory monitoring, echo, and pacemaker indication assessment
• SDE Cohort (Tier 2): Remote pacemaker monitoring integration, post-implant annual review
• SDE Snapshot (rapid evaluation): Urgent same-day evaluation for patients with documented symptomatic pauses or syncope with bradycardia

Sex Differences in Pacemaker Therapy — Indications, Complications, and Outcomes

9.1 The Underrepresentation of Women in Pacemaker Trials

Women constitute approximately 45-50% of pacemaker recipients in the US in clinical practice, yet they represent a smaller fraction of enrollees in the landmark pacemaker trials. The UKPACE trial enrolled 34% women; the MOST trial enrolled 42% women. Neither was powered for sex-stratified outcome analyses. The result is that pacemaker mode selection recommendations, complication rate benchmarks, and programming defaults have been primarily established in male-majority populations 3 / Early .

9.2 Complication Rate Differences by Sex

Women receiving permanent pacemakers have a modestly higher rate of procedure-related complications than men, particularly pneumothorax (0.8-1.2% in women vs 0.4-0.6% in men in registry data) and lead dislodgement 4 / Promising . The pneumothorax difference is attributed to smaller average subclavian vein diameter in women and to differences in body habitus that affect the axillary-subclavian venous access angle. Centers with high pacemaker volume and axillary vein access protocols (rather than subclavian puncture) have lower pneumothorax rates across both sexes.

The practical implication: when patients ask about pacemaker implantation risk, the standard quoted complication rate of “1-2% overall” should be understood as an average that slightly understates risk for women and slightly overstates it for men in experienced-center data. The more clinically meaningful conversation is about the specific operator’s complication rate at the specific institution.

9.3 Pacemaker Syndrome — More Common in Women?

Pacemaker syndrome (hemodynamic deterioration caused by atrioventricular dyssynchrony during VVI pacing) may be more symptomatic in women than in men. The MOST trial data showed that women randomized to VVIR pacing reported more symptoms of pacemaker syndrome than men at comparable AV dyssynchrony rates 4 / Promising . The mechanism is not fully established; it may reflect higher rates of diastolic dysfunction in women (diastolic dysfunction magnifies the hemodynamic penalty of losing AV synchrony) or greater sensitivity to blood pressure drops in women with lower average resting systolic blood pressure.

The practical implication: DDDR pacing is generally preferable over VVIR in patients with intact sinus node function who require AV nodal pacing, and this preference may be stronger in women. The 2018 guideline Class I recommendation for physiological dual-chamber pacing over VVIR (when technically feasible and not otherwise contraindicated) should be applied without reservation in women.

9.4 The His Bundle and Conduction System Pacing — An Emerging Sex Issue

His bundle pacing and left bundle branch area pacing preserve ventricular synchrony by capturing the native conduction system below the AV node. Published registries suggest that women have a slightly higher success rate for His bundle capture at typical programmed output levels due to anatomical proximity of the His bundle to the septum in women’s smaller hearts 3 / Early . This is an emerging area; the sex-stratified data are observational and should be treated as hypothesis-generating. Conduction system pacing is currently a Class IIa indication in selected patients and is discussed in the SDE Foundations article on leadless and conduction system pacing (cross-link to SDE-F-DEVI-011).

Technical Notes on Pacemaker Engineering

10.1 The Modern Pacemaker Generator

A dual-chamber pacemaker generator contains:

• A lithium-iodine battery (typically 1.5-2.0 Ah capacity) providing 8-15 years of service life at typical programmed output levels
• A hybrid circuit performing sensing amplification, output timing, telemetry encoding, and diagnostic data collection
• A titanium housing providing electromagnetic shielding and biocompatibility
• A connector block (IS-1 standard for most devices) accepting two lead connectors (atrial and ventricular)
• An antenna for radio-frequency telemetry with the programmer wand

Generator dimensions vary by model and manufacturer but typically measure 45-55 mm in length, 35-45 mm in width, and 6-8 mm in thickness, weighing 20-30 grams. The generator is implanted in a subcutaneous pocket typically created in the prepectoral region (below the clavicle, above the pectoralis major fascia). In thin patients, the generator may create a visible contour; in patients with adequate subcutaneous tissue, it is not visible. The generator may be palpable through the skin, which is expected and benign.

10.2 Lead Engineering and the Pacing-Sensing Threshold

The pacemaker lead delivers energy from the generator to the myocardium through a tip electrode in contact with endocardial tissue. The pacing threshold is the minimum energy (in volts) that reliably captures (depolarizes) the adjacent myocardium. At implant, thresholds are tested and the device is programmed to deliver output 2-3 times the pacing threshold at the same pulse width, providing a safety margin. Over the first 4-8 weeks post-implant, an “acute rise” in threshold occurs as fibrotic encapsulation forms around the lead tip, followed by threshold stabilization. Modern steroid-eluting lead tips (most contemporary leads use a small dexamethasone depot at the tip) minimize this acute threshold rise 5 / Solid .

The sensing threshold is the minimum electrogram amplitude (in millivolts) that the amplifier detects as a cardiac event. If the intrinsic cardiac signal is too small, the device will not sense appropriately and may pace at the programmed lower rate even when the intrinsic rhythm is faster (a problem called “undersensing”). If sensing is too sensitive, the amplifier may detect extracardiac electrical noise (myopotentials, lead fracture signals) as cardiac events and inhibit pacing inappropriately (oversensing). Threshold testing at every device interrogation documents that both pacing and sensing remain within appropriate margins.

10.3 Rate Response: How Accelerometers and Minute Ventilation Sensing Work

Rate-responsive pacing allows the device to increase the pacing rate in response to physical activity, addressing chronotropic incompetence in patients who cannot raise their heart rate normally with exercise. Two dominant sensing technologies:

Accelerometer: Detects body movement as a mechanical vibration signal. Simple, reliable, and consumes minimal battery power. Responds immediately to walking or running. Disadvantage: responds to external vibration (bumpy car ride, vibration from machinery) and may not respond to activities that increase metabolic demand without body movement (isometric exercise, emotional stress).

Minute ventilation sensor: Measures the thoracic impedance change with each breath, deriving a surrogate for respiratory rate and tidal volume. This tracks minute ventilation (a metabolic demand surrogate) better than accelerometry during isometric or upper-body exercise. Disadvantage: requires more complex lead technology, responds to hyperventilation from anxiety (false rate increase), and is susceptible to noise from lead flexion.

Most modern rate-responsive devices use a blended sensor combining both modalities, with automatic weighting between them based on the type of detected activity. Rate response parameters should be optimized individually; a sedentary 78-year-old with sick sinus syndrome and a physically active 55-year-old with AV block have very different rate response needs, and factory-default settings are rarely ideal for either.

The WRAP-IT Trial and Infection Prevention

11.1 CIED Infection — The Clinical Stakes

Cardiovascular implantable electronic device (CIED) infection is a potentially devastating complication. Pocket infection (infection of the subcutaneous generator pocket) occurs in approximately 0.5-1.0% of de novo implants. Lead infection, which extends bacteremia along the intravascular lead, carries a much higher mortality (in-hospital mortality for CIED lead infection is 10-15% in published registries, driven largely by the need for complete device extraction under general anesthesia with the risk of vegetations on the lead embolizing during extraction). Staphylococcus aureus is the most common pathogen; Staphylococcus epidermidis (coagulase-negative staph) is common in late infections.

11.2 WRAP-IT in Detail

WRAP-IT (Tarakji KG, et al., NEJM 2019; DOI: 10.1056/NEJMoa1901683) enrolled 6,983 patients undergoing CIED implantation or revision and randomized them 1:1 to receive an antibacterial envelope (Tyrx, containing rifampin and minocycline, which elute over 7 days post-implant) or no envelope, in addition to standard IV antibiotic prophylaxis. The primary endpoint was CIED infection within 12 months.

Results: CIED infection occurred in 0.7% of the envelope group vs 1.2% of the control group (HR 0.60, 95% CI 0.36-0.98, p = 0.04) 5 / Solid . The absolute risk reduction was 0.5 percentage points; the number needed to treat was 200. In pre-specified subgroups, the benefit was larger in patients undergoing pocket revision or system upgrade (higher baseline infection risk) than in de novo implantation.

What WRAP-IT did not show: the trial was not adequately powered for all-cause mortality. The clinical significance of a 0.5% absolute risk reduction in infection must be weighed against the cost of the envelope ($1,000-1,300 per unit). Current ACC/AHA guidelines note the WRAP-IT result as supporting the use of antibacterial envelopes in higher-risk CIED procedures (IIa) while acknowledging that routine use in all low-risk de novo implants generates a high cost per infection prevented.

11.3 Patient Counseling on CIED Infection

The patient scheduled for pacemaker implantation should understand: the risk of infection is real but low. Prophylactic IV antibiotics (typically cefazolin) are given before the incision in all cases. Post-implant, the wound should be inspected for redness, drainage, or skin erosion at each follow-up visit. Any wound changes within 6 months of implantation should prompt urgent evaluation. Fever, bacteremia, or new symptoms in the device pocket area at any time after implantation require immediate medical evaluation and blood cultures, because device infection can present months to years after the original implant if an overlying infection (dental, urinary, skin) seeds the device during bacteremia.

The Three Questions Every Patient Should Ask Before Pacemaker Implantation

The Decisions and Trade-Offs section of this article established the clinical decision framework. These three questions operationalize that framework for the patient sitting across from their cardiologist:

Question 1: “Is pacemaker implantation the only option, or is there a reversible cause of my bradycardia that could be corrected first?”

Many bradycardias are iatrogenic (caused by medications: beta-blockers, diltiazem, verapamil, digoxin, amiodarone) or are reversible conditions (hypothyroidism, Lyme carditis, sleep apnea-related nocturnal bradycardia). Before implanting a permanent device, the cardiologist should confirm that reversible causes have been excluded and that the bradycardia is intrinsic to the conduction system, not pharmacologically induced. Every patient deserves a clear answer to this question before signing the pacemaker consent form.

Question 2: “What pacing mode are you recommending, and why is that mode appropriate for my specific heart anatomy and physiology?”

DDDR pacing is not universally superior to VVIR; conduction system pacing is not appropriate for all patients. The patient who asks this question will learn something about their specific anatomy (intact sinus node function vs sinus node dysfunction) and about the cardiologist’s reasoning. A cardiologist who cannot answer this question specifically has not fully individualized the pacemaker prescription.

Question 3: “What is your center’s complication rate for pacemaker implantation, and how does your complication rate compare to the national benchmark?”

National benchmark complication rates (STS database, Medicare administrative data) provide a reference standard. An honest cardiologist or proceduralist can answer this question. A cardiologist who says “complications are very rare” without citing a number is not answering the question. The patient is entitled to know whether they are receiving care at a high-volume center with documented low complication rates or at a lower-volume program where the published data suggest higher procedural risk.

Remote Monitoring and the Future of Pacemaker Follow-Up in Rural Illinois

13.1 The Remote Monitoring Standard

All major pacemaker manufacturers (Medtronic, Abbott, Boston Scientific, Biotronik) offer remote monitoring systems that transmit device interrogation data nightly from a bedside transmitter to a secure physician portal. The 2014 HRS consensus statement on remote monitoring (Wilkoff BL, et al., Heart Rhythm 2014; DOI: 10.1016/j.hrthm.2014.05.029) established daily remote monitoring as the standard for CIED follow-up, superseding quarterly in-person clinic visits as the primary surveillance mechanism for routine device function 5 / Solid .

Remote monitoring detects clinically significant events earlier than in-person follow-up. The CONNECT trial (Crossley GH, et al., JACC 2011; DOI: 10.1016/j.jacc.2011.01.005) demonstrated that remote monitoring reduced time to clinical decision by a median of 4.6 days compared to conventional follow-up, and was associated with a 50% reduction in cardiovascular hospitalizations in the remote monitoring group 5 / Solid . This result has been replicated in multiple subsequent registries.

13.2 Rural Illinois Application

For pacemaker patients in rural Illinois (Danville, Decatur, Champaign, Quincy, and the surrounding rural counties), remote monitoring eliminates the most significant barrier to adequate CIED follow-up: the requirement to travel 30-90 minutes to a cardiology clinic for a routine device interrogation. A patient in rural Vermilion County who has a Medtronic pacemaker with the MyCareLink bedside transmitter uploads a device interrogation to the Medtronic Carelink portal every night. The cardiologist at Carle Foundation Hospital reviews the interrogation remotely without the patient leaving their home.

Clinically urgent findings (lead impedance change, battery depletion, threshold rise above the pacing safety margin, detected AF) generate automatic alerts to the cardiologist’s inbox or paging system within hours of detection. For the rural patient who might otherwise defer a 90-minute drive to Urbana until symptoms become severe, the remote monitoring system closes the gap between device finding and clinical response.

13.3 SDE Integration for Pacemaker Patients

Patients in the SDE Cohort program who have pacemaker implants are enrolled in remote monitoring through their device manufacturer’s portal as a condition of their SDE membership. Monthly remote data review is integrated into the SDE clinical rounds process. The clinical team reviews:

• Battery voltage and projected longevity (battery depletion alerts at less than 6 months remaining)
• Lead impedances (sudden change in impedance signals lead fracture or insulation break)
• Pacing and sensing thresholds (threshold rise may signal lead dislodgement, cardiac remodeling, or pericardial effusion)
• Detected arrhythmia data (AF burden, NSVT episodes, mode switches)
• Activity logs (percent paced, daily heart rate trends)

This monthly review provides a level of device surveillance that exceeds the standard annual in-person interrogation recommended in most pacemaker follow-up protocols. For high-risk patients (those with pacemaker-dependency, those in whom detecting AF would change anticoagulation management, those with remote implantation sites), the frequency of SDE remote review is increased to biweekly.